Genmab A/S (NASDAQ:GMAB) Stock Rating Lowered by Wall Street Zen

Genmab A/S (NASDAQ:GMAB - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday.

Several other research analysts also recently weighed in on GMAB. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Finally, Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Stock Down 1.2%

NASDAQ:GMAB opened at $22.82 on Friday. The stock's 50 day moving average price is $20.56 and its 200 day moving average price is $20.74. The company has a market capitalization of $14.63 billion, a PE ratio of 13.11, a P/E/G ratio of 2.65 and a beta of 0.96. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The firm had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, sell-side analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in Genmab A/S during the fourth quarter valued at about $2,463,000. AIMZ Investment Advisors LLC acquired a new position in shares of Genmab A/S during the fourth quarter worth about $3,525,000. Northern Trust Corp lifted its stake in shares of Genmab A/S by 18.8% during the fourth quarter. Northern Trust Corp now owns 599,381 shares of the company's stock worth $12,509,000 after purchasing an additional 94,858 shares in the last quarter. Sei Investments Co. lifted its stake in shares of Genmab A/S by 55.2% during the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company's stock worth $1,205,000 after purchasing an additional 20,525 shares in the last quarter. Finally, LPL Financial LLC lifted its stake in shares of Genmab A/S by 3.3% during the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company's stock worth $4,079,000 after purchasing an additional 6,288 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.